298 related articles for article (PubMed ID: 22789565)
1. Targeting c-kit in the therapy of mast cell disorders: current update.
El-Agamy DS
Eur J Pharmacol; 2012 Sep; 690(1-3):1-3. PubMed ID: 22789565
[TBL] [Abstract][Full Text] [Related]
2. Tumor-intrinsic and -extrinsic roles of c-Kit: mast cells as the primary off-target of tyrosine kinase inhibitors.
Pittoni P; Piconese S; Tripodo C; Colombo MP
Oncogene; 2011 Feb; 30(7):757-69. PubMed ID: 21057534
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in the understanding of mastocytosis: the role of KIT mutations.
Orfao A; Garcia-Montero AC; Sanchez L; Escribano L;
Br J Haematol; 2007 Jul; 138(1):12-30. PubMed ID: 17555444
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological targeting of the KIT growth factor receptor: a therapeutic consideration for mast cell disorders.
Jensen BM; Akin C; Gilfillan AM
Br J Pharmacol; 2008 Aug; 154(8):1572-82. PubMed ID: 18500355
[TBL] [Abstract][Full Text] [Related]
5. Stem cell factor and its receptor c-Kit as targets for inflammatory diseases.
Reber L; Da Silva CA; Frossard N
Eur J Pharmacol; 2006 Mar; 533(1-3):327-40. PubMed ID: 16483568
[TBL] [Abstract][Full Text] [Related]
6. Activation of KIT modulates the function of tumor necrosis factor-related apoptosis-inducing ligand receptor (TRAIL-R) in mast cells.
Förster A; Grotha SP; Seeger JM; Rabenhorst A; Gehring M; Raap U; Létard S; Dubreuil P; Kashkar H; Walczak H; Roers A; Hartmann K
Allergy; 2015 Jul; 70(7):764-74. PubMed ID: 25833810
[TBL] [Abstract][Full Text] [Related]
7. Tyrosine Kinase Inhibition in Mastocytosis: KIT and Beyond KIT.
Bibi S; Arock M
Immunol Allergy Clin North Am; 2018 Aug; 38(3):527-543. PubMed ID: 30007468
[TBL] [Abstract][Full Text] [Related]
8. Activation of MAP kinases, pp90rsk and pp70-S6 kinases in mouse mast cells by signaling through the c-kit receptor tyrosine kinase or Fc epsilon RI: rapamycin inhibits activation of pp70-S6 kinase and proliferation in mouse mast cells.
Tsai M; Chen RH; Tam SY; Blenis J; Galli SJ
Eur J Immunol; 1993 Dec; 23(12):3286-91. PubMed ID: 7504992
[TBL] [Abstract][Full Text] [Related]
9. Phosphatidylinositol 3'-kinase is required for growth of mast cells expressing the kit catalytic domain mutant.
Shivakrupa R; Bernstein A; Watring N; Linnekin D
Cancer Res; 2003 Aug; 63(15):4412-9. PubMed ID: 12907613
[TBL] [Abstract][Full Text] [Related]
10. Aberrant autophosphorylation of c-Kit receptor in canine mast cell tumor cell lines.
Takeuchi Y; Fujino Y; Watanabe M; Nakagawa T; Ohno K; Sasaki N; Sugano S; Tsujimoto H
Vet Immunol Immunopathol; 2010 Oct; 137(3-4):208-16. PubMed ID: 20591500
[TBL] [Abstract][Full Text] [Related]
11. Transient production of stem cell factor in dermal cells but increasing expression of Kit receptor in mast cells during normal wound healing.
Huttunen M; Naukkarinen A; Horsmanheimo M; Harvima IT
Arch Dermatol Res; 2002 Oct; 294(7):324-30. PubMed ID: 12373338
[TBL] [Abstract][Full Text] [Related]
12. KIT and mastocytosis.
Lim KH; Pardanani A; Tefferi A
Acta Haematol; 2008; 119(4):194-8. PubMed ID: 18566536
[TBL] [Abstract][Full Text] [Related]
13. Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor.
Georgin-Lavialle S; Lhermitte L; Suarez F; Yang Y; Letard S; Hanssens K; Feger F; Renand A; Brouze C; Canioni D; Asnafi V; Chandesris MO; Aouba A; Gineste P; Macintyre E; Mansfield CD; Moussy A; Lepelletier Y; Dubreuil P; Hermine O
Eur J Haematol; 2012 Jul; 89(1):47-52. PubMed ID: 22324351
[TBL] [Abstract][Full Text] [Related]
14. Clonality and molecular pathogenesis of mastocytosis.
Akin C
Acta Haematol; 2005; 114(1):61-9. PubMed ID: 15995326
[TBL] [Abstract][Full Text] [Related]
15. Neuropsychological features of adult mastocytosis.
Moura DS; Georgin-Lavialle S; Gaillard R; Hermine O
Immunol Allergy Clin North Am; 2014 May; 34(2):407-22. PubMed ID: 24745683
[TBL] [Abstract][Full Text] [Related]
16. C-Kit controls IL-1β-induced effector functions in HMC-cells.
Drube S; Schmitz F; Göpfert C; Weber F; Kamradt T
Eur J Pharmacol; 2012 Jan; 675(1-3):57-62. PubMed ID: 22173128
[TBL] [Abstract][Full Text] [Related]
17. The biology of Kit in disease and the application of pharmacogenetics.
Akin C; Metcalfe DD
J Allergy Clin Immunol; 2004 Jul; 114(1):13-9; quiz 20. PubMed ID: 15241338
[TBL] [Abstract][Full Text] [Related]
18. [Therapeutically relevant mutations in the receptor tyrosine kinase KIT in mastocytosis].
Sotlar K
Verh Dtsch Ges Pathol; 2007; 91():169-76. PubMed ID: 18314612
[TBL] [Abstract][Full Text] [Related]
19. Mastocytosis: advances in diagnosis and treatment.
Hungness SI; Akin C
Curr Allergy Asthma Rep; 2007 Jul; 7(4):248-54. PubMed ID: 17547845
[TBL] [Abstract][Full Text] [Related]
20. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm.
Longley BJ; Tyrrell L; Lu SZ; Ma YS; Langley K; Ding TG; Duffy T; Jacobs P; Tang LH; Modlin I
Nat Genet; 1996 Mar; 12(3):312-4. PubMed ID: 8589724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
